ESR2 and breast carcinoma: Specifically, we evaluated the effects of lumican on various types of breast cancer cells; one positive for ERα (MCF-7, low invasive) and another positive for the ERβ (MDA-MB-231, highly invasive) before and after knockdown of these ERs, respectively.